Malaria Update
Sanofi launches cut-price malaria pill for Africa
LONDON (Reuters) - French drugmaker Sanofi-Aventis has launched a new cheap and easy-to-take combination pill to fight malaria that could help reduce deaths from the killer disease in Africa, it said on Thursday.
Sanofi is working with the Drugs for Neglected Diseases initiative (DNDi) -- a group backed by charity Medecins Sans Frontieres -- and will sell the drug at no profit for less than $1 for adults and 50 cents for children under five years old.
The two-in-one pill is designed primarily for Africa, where a child dies of malaria every 30 seconds, but an amended form is also in the works for Latin America, South East Asia and India, where there are different types of malaria.
*****
In an unusual move for a drugmaker, Sanofi has decided not to patent the medicine, leaving the door open for generic companies to copy it and produce their own cheap versions.
Read the whole, brief article here:
Reuter's Canada: "Sanofi launches cut-price malaria pill for Africa"
LONDON (Reuters) - French drugmaker Sanofi-Aventis has launched a new cheap and easy-to-take combination pill to fight malaria that could help reduce deaths from the killer disease in Africa, it said on Thursday.
Sanofi is working with the Drugs for Neglected Diseases initiative (DNDi) -- a group backed by charity Medecins Sans Frontieres -- and will sell the drug at no profit for less than $1 for adults and 50 cents for children under five years old.
The two-in-one pill is designed primarily for Africa, where a child dies of malaria every 30 seconds, but an amended form is also in the works for Latin America, South East Asia and India, where there are different types of malaria.
*****
In an unusual move for a drugmaker, Sanofi has decided not to patent the medicine, leaving the door open for generic companies to copy it and produce their own cheap versions.
Read the whole, brief article here:
Reuter's Canada: "Sanofi launches cut-price malaria pill for Africa"
posted by Heather at
10:27 AM
0 Comments:
Post a Comment
<< Home